Atai Life Sciences Reports First Quarter 2023 Financial Resu

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the... | May 11, 2023

Related Keywords

Berlin , Germany , Allan Malievsky , Deuterated Etifoxine , Stephen Bardin , Society For Biological Psychiatry , Development Rd Expenses , Life Sciences , Exchange Commission , Securities Exchange , Hercules Capital Inc , Cognitive Impairment Associated , Pivotal Trial , Florian Brand , Pipeline Recent Highlights , Pro Cognitive Neuromodulator , Cognitive Battery , Anxiety Disorders , Biological Psychiatry , Psilocybin Therapy , Anorexia Nervosa , Cash Equivalents , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Hercules Capital , Financial Condition , Atai Life Sciencesnv Stock Exchange , News , Information , Press Release , First , Patient , Hosed , N , The , Hase , Tb , Study , F , Cognitive , Impairment , Ssociated , Ith , Resented , D , Data , Rom , Ompleted , , Which , Uggest Atai Nl0015000dx5 ,